Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...
The U.S. Food and Drug Administration (FDA) recently approved the use of Darzalex Faspro (daratumumab and hyaluronidase-fihj) ...
Investing.com -- Johnson & Johnson (NYSE:JNJ) announced Monday that the European Commission has approved subcutaneous Rybrevant (amivantamab) for every-three-week and every-four-week dosing schedules ...
FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and ...
The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).
Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), ...
Phase 1a/b safety study of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer (ADVANCED-1). This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...
Visceral fat vs subcutaneous fat are the key differences, health risks, and why visceral fat is considered more dangerous.
Canada's health regulator has approved Merck's new under-the-skin version of its cancer drug Keytruda, offering an alternative to the current intravenous infusion. Health Canada has approved Keytruda ...
PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...
When we're thinking of slimming down, we're usually referring to losing subcutaneous fat. This is the fat that lies right beneath the skin and creates that jiggly sensation. Excess subcutaneous fat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results